Our commercial group is now fully focused on launch preparations for vilazodone, subject to effective completion of FDA review, and we continue to manage our cash and other resources as we move nearer toward this essential milestone. Related StoriesFlorida Institute finalizes funding agreement with Genetic NetworksBerkeley Laboratory scientists identify genetic elements that influence neurological disorders and body weightMedUni Vienna experts discover genetic reason behind a rare diseaseUnder the conditions of the asset buy agreement, Transgenomic obtained Clinical Data’s FAMILION category of genetic lab tests for inherited heart diseases and biomarkers underlying the PGxPredict tests which predict medication response, along with the operational infrastructure that helps the continuing business.This is the main summary of a survey analysis led by David L. Brown, MD, Professor Medication in the Division of Cardiovascular Medication at Stony Brook University School of Medicine. The results are published online in Circulation: Cardiovascular Quality and Outcomes. Dr. Coauthors and Brown of the paper, ‘Influence of Cardiac Doctor Report Cards on Patient Referral by Cardiologists in NY State After twenty years of Public Reporting,’ comprehensive their findings of the survey evaluation, including responses from 317 New York cardiologists in 2011. They discovered that only 25 % of the cardiologists indicated the report cards acquired a ‘moderate’ or ‘substantial’ impact on referral decisions. Additionally, the conversation of the report card data with sufferers remained minimal, as 71 % of the cardiologists indicated that they didn’t discuss the reviews with sufferers.